Using a capture assay for pharmacokinetic characterization, immobilized anti-idiotype scFv Hc5 (then named as LRID03) was used as a surrogate ligand for CD22 to determine the serum levels of residual SM03 in lymphoma patients treated with the antibody. This evidence concerns the gene CD22 and lymphoma.